Latest Quarterly Report
Filed: 2026-05-07
Key Insights
- Company is a large accelerated filer in the biotechnology sector with operations focused on immunotherapy programs including CDX-622, Barzvolvolimab (anti-KIT), and other pipeline candidates as of Q1 2026.
- Filing shows multiple equity financing activities including an underwritten public offering completed in April 2026 (post-quarter end), indicating the company is actively raising capital to fund operations and clinical development.
- The company maintains contingent milestone obligations related to Kolltan Pharmaceuticals acquisition (dating back to 2016 and 2022), suggesting potential future payments based on development or commercial achievements of acquired assets.
- Company has registered securities under an equity offering sales agreement as of March 31, 2026, demonstrating ongoing capital market access for funding needs as a development-stage biopharmaceutical company.